Selected research
Industry Growth & Trends
Global Biosimilar Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Biosimilar market include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Biosimilar market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Biosimilar market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biosimilar market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biosimilar.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Biosimilar market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Biosimilar Market by Company
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Biosimilar Segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Biosimilar Segment by Application
Cancer
Immunological Diseases
Diabetes
Others
Biosimilar Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Biosimilar companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Biosimilar Monoclonal Antibodies
- Biosimilar Insulin
- Others
Applications
- Cancer
- Immunological Diseases
- Diabetes
- Others
Companies covered
- Qilu Pharmaceutical
- Bio-Thera
- Zhejiang Hisun
- Shanghai Henlius
- Innovent Biologics
- Jiangsu Hengrui
- Gan&Lee
- Tonghua Dongbao
- United Laboratory
- 3SBIO
- Luye Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Biosimilar Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Biosimilar Market Size by Region (2021-2032)
- 1.4.1 Global Biosimilar Market Size by Region (2021-2026)
- 1.4.2 Global Biosimilar Market Size by Region (2027-2032)
- 1.5 Key Regions Biosimilar Market Size (2021-2032)
- 1.5.1 North America Biosimilar Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Biosimilar Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Biosimilar Market Size Growth Rate (2021-2032)
- 1.5.4 South America Biosimilar Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Biosimilar Market Size Growth Rate (2021-2032)
2 Biosimilar Market by Type
- 2.1 Type Introduction
- 2.1.1 Biosimilar Monoclonal Antibodies
- 2.1.2 Biosimilar Insulin
- 2.1.3 Others
- 2.2 Global Biosimilar Market Size by Type
- 2.2.1 Global Biosimilar Market Size Overview by Type (2021-2032)
- 2.2.2 Global Biosimilar Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Biosimilar Market Size Forecasted by Type (2027-2032)
- 2.3 Global Biosimilar Market Size by Regions
- 2.3.1 North America Biosimilar Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Biosimilar Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Biosimilar Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Biosimilar Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Biosimilar Market Size Breakdown by Type (2021-2026)
3 Biosimilar Market by Application
- 3.1 Type Introduction
- 3.1.1 Cancer
- 3.1.2 Immunological Diseases
- 3.1.3 Diabetes
- 3.1.4 Others
- 3.2 Global Biosimilar Market Size by Application
- 3.2.1 Global Biosimilar Market Size Overview by Application (2021-2032)
- 3.2.2 Global Biosimilar Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Biosimilar Market Size Forecasted by Application (2027-2032)
- 3.3 Global Biosimilar Market Size by Regions
- 3.3.1 North America Biosimilar Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Biosimilar Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Biosimilar Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Biosimilar Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Biosimilar Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Biosimilar Industry Trends
- 4.2 Biosimilar Industry Drivers
- 4.3 Biosimilar Industry Opportunities and Challenges
- 4.4 Biosimilar Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Biosimilar Revenue (2021-2026)
- 5.2 Global Biosimilar Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Biosimilar Key Company Headquarters & Area Served
- 5.4 Global Biosimilar Company, Product Type & Application
- 5.5 Global Biosimilar Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Biosimilar Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Biosimilar Players Market Share by Revenue in 2025
- 5.6.3 2025 Biosimilar Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Qilu Pharmaceutical
- 6.1.1 Qilu Pharmaceutical Company Information
- 6.1.2 Qilu Pharmaceutical Business Overview
- 6.1.3 Qilu Pharmaceutical Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Qilu Pharmaceutical Biosimilar Product Portfolio
- 6.1.5 Qilu Pharmaceutical Recent Developments
- 6.2 Bio-Thera
- 6.2.1 Bio-Thera Company Information
- 6.2.2 Bio-Thera Business Overview
- 6.2.3 Bio-Thera Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Bio-Thera Biosimilar Product Portfolio
- 6.2.5 Bio-Thera Recent Developments
- 6.3 Zhejiang Hisun
- 6.3.1 Zhejiang Hisun Company Information
- 6.3.2 Zhejiang Hisun Business Overview
- 6.3.3 Zhejiang Hisun Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Zhejiang Hisun Biosimilar Product Portfolio
- 6.3.5 Zhejiang Hisun Recent Developments
- 6.4 Shanghai Henlius
- 6.4.1 Shanghai Henlius Company Information
- 6.4.2 Shanghai Henlius Business Overview
- 6.4.3 Shanghai Henlius Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Shanghai Henlius Biosimilar Product Portfolio
- 6.4.5 Shanghai Henlius Recent Developments
- 6.5 Innovent Biologics
- 6.5.1 Innovent Biologics Company Information
- 6.5.2 Innovent Biologics Business Overview
- 6.5.3 Innovent Biologics Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Innovent Biologics Biosimilar Product Portfolio
- 6.5.5 Innovent Biologics Recent Developments
- 6.6 Jiangsu Hengrui
- 6.6.1 Jiangsu Hengrui Company Information
- 6.6.2 Jiangsu Hengrui Business Overview
- 6.6.3 Jiangsu Hengrui Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Jiangsu Hengrui Biosimilar Product Portfolio
- 6.6.5 Jiangsu Hengrui Recent Developments
- 6.7 Gan&Lee
- 6.7.1 Gan&Lee Company Information
- 6.7.2 Gan&Lee Business Overview
- 6.7.3 Gan&Lee Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Gan&Lee Biosimilar Product Portfolio
- 6.7.5 Gan&Lee Recent Developments
- 6.8 Tonghua Dongbao
- 6.8.1 Tonghua Dongbao Company Information
- 6.8.2 Tonghua Dongbao Business Overview
- 6.8.3 Tonghua Dongbao Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Tonghua Dongbao Biosimilar Product Portfolio
- 6.8.5 Tonghua Dongbao Recent Developments
- 6.9 United Laboratory
- 6.9.1 United Laboratory Company Information
- 6.9.2 United Laboratory Business Overview
- 6.9.3 United Laboratory Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 United Laboratory Biosimilar Product Portfolio
- 6.9.5 United Laboratory Recent Developments
- 6.10 3SBIO
- 6.10.1 3SBIO Company Information
- 6.10.2 3SBIO Business Overview
- 6.10.3 3SBIO Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 3SBIO Biosimilar Product Portfolio
- 6.10.5 3SBIO Recent Developments
- 6.11 Luye Pharma
- 6.11.1 Luye Pharma Company Information
- 6.11.2 Luye Pharma Business Overview
- 6.11.3 Luye Pharma Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Luye Pharma Biosimilar Product Portfolio
- 6.11.5 Luye Pharma Recent Developments
7 North America
- 7.1 North America Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Biosimilar Market Size by Country (2021-2026)
- 7.3 North America Biosimilar Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Biosimilar Market Size by Country (2021-2026)
- 8.3 Europe Biosimilar Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Biosimilar Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Biosimilar Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Biosimilar Market Size by Country (2021-2026)
- 10.3 South America Biosimilar Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Biosimilar Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Biosimilar Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst